Phenotypic analyses of tumor-infiltrating cells revealed significantly lower percentages of PD-1+ (p = 0.009) and FoxP3+ (p = 0.028), and a higher percentage of NKp46+ (p = 0.011) CD3+CD49+ cells in the metformin-treated group (Figure 3F–H). The gene discussed is NCR1; the disease is neoplasm.